- Home
- AZN
AZN
AstraZeneca PLC
as of 07-23-2026 4:00pm EST
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | 96100 | City: | N/A |
| Market Cap: | 316.4B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $71.49 - $212.71 | Next Earning Date: | 04-29-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 10.34% | Revenue Growth (next year): | 6.43% |
| P/E Ratio: | 31.91 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +1.26% |
Compare AZN vs Leading Stocks
See how AZN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.